A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1178 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-24

Study Completion Date

2031-01-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, researchers will learn more about the effects of diroximel fumarate (DRF), also known as VUMERITY®, when taken during pregnancy in people with multiple sclerosis, also known as MS. In MS, the immune system attacks the nerves in the brain and spinal cord. The affected areas are called lesions. The damage makes it difficult for the brain and spinal cord to function and send messages throughout the body. MS can be a progressive disease, which means it may get worse over time. In relapsing forms of MS (RMS), new symptoms may happen, and existing symptoms may get better or worse over time. DRF is an approved drug that is used to treat people with RMS.

This is known as an "observational" study, which collects health information about study participants without changing their medical care. The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are:

* Those who took DRF during their pregnancy
* Those who took other drugs for RMS during their pregnancy, but not DRF
* Those who did not take any drugs for RMS during their pregnancy

The main question researchers want to learn about in this study is:

• How many participants' babies were born with major congenital malformations (MCMs)? MCMs are problems with how a baby's body forms before birth.

Researchers will also learn more about:

* Loss of the baby before 20 weeks of pregnancy
* Loss of the baby at and after 20 weeks of pregnancy
* How many babies are born early (at or before 37 weeks)
* How many babies are small for their age while in the participant's uterus
* How many babies are born with any sign of life

This study will be done as follows:

* Participants with RMS can join this study if they become pregnant from 29th October 2019 to 31st July 2030. Information will start being collected when the participant decides to join the study.
* The participants' medical records will be reviewed 2 times during the study - once when the study is halfway done, and one at the end of the study.
* Each participant will be in the study until the end of their pregnancy. Each baby will be in the study for up to 1 year after birth.
* The study is planned to end by 30th April 2031.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biogen Multiple Sclerosis Pregnancy Exposure Registry

NCT01911767

Multiple Sclerosis Exposure During Pregnancy

COMPLETED

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

NCT05767736

Multiple Sclerosis

ACTIVE_NOT_RECRUITING

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

NCT05083923

Relapsing Forms of Multiple Sclerosis

COMPLETED PHASE3

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770

Relapsing-Remitting Multiple Sclerosis

COMPLETED PHASE3

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01838668

Relapsing-Remitting Multiple Sclerosis Multiple Sclerosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is to estimate the prevalence of major congenital malformations (MCMs) and compare the prevalence between the diroximel fumarate (DRF) and comparator groups. The secondary objectives of the study are to estimate the incidence of spontaneous abortion (SA) and compare the incidence between the DRF and comparator groups; to estimate the incidence of preterm birth and compare the incidence between the DRF and comparator groups; to estimate the incidence of stillbirth and compare the incidence between the DRF and comparator groups; to estimate the prevalence of small for gestational age (SGA) and compare the prevalence between the DRF and comparator groups; and to estimate the incidence of live birth and compare the incidence between the DRF and comparator groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diroximel Fumarate (DRF)

Pregnant women with MS who were exposed to DRF.

Diroximel Fumarate

Intervention Type DRUG

Administered as specified in the treatment arm.

Non-DRF

Pregnant women with MS who were exposed to disease-modifying therapies (DMTs) other than DRF.

Alemtuzumab

Intervention Type BIOLOGICAL

Administered as specified in the treatment arm.

Fingolimod

Intervention Type DRUG

Administered as specified in the treatment arm.

Glatiramer acetate

Intervention Type DRUG

Administered as specified in the treatment arm.

Interferon beta

Intervention Type BIOLOGICAL

Administered as specified in the treatment arm.

Natalizumab

Intervention Type BIOLOGICAL

Administered as specified in the treatment arm.

Ocrelizumab

Intervention Type BIOLOGICAL

Administered as specified in the treatment arm.

Ofatumumab

Intervention Type BIOLOGICAL

Administered as specified in the treatment arm.

Ozanimod

Intervention Type DRUG

Administered as specified in the treatment arm.

Peginterferon beta-1a

Intervention Type BIOLOGICAL

Administered as specified in the treatment arm.

Ponesimod

Intervention Type DRUG

Administered as specified in the treatment arm.

Siponimod

Intervention Type DRUG

Administered as specified in the treatment arm.

Non-DMT

Pregnant women with MS who were not exposed to DMTs.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diroximel Fumarate

Administered as specified in the treatment arm.

Intervention Type DRUG

Alemtuzumab

Administered as specified in the treatment arm.

Intervention Type BIOLOGICAL

Fingolimod

Administered as specified in the treatment arm.

Intervention Type DRUG

Glatiramer acetate

Administered as specified in the treatment arm.

Intervention Type DRUG

Interferon beta

Administered as specified in the treatment arm.

Intervention Type BIOLOGICAL

Natalizumab

Administered as specified in the treatment arm.

Intervention Type BIOLOGICAL

Ocrelizumab

Administered as specified in the treatment arm.

Intervention Type BIOLOGICAL

Ofatumumab

Administered as specified in the treatment arm.

Intervention Type BIOLOGICAL

Ozanimod

Administered as specified in the treatment arm.

Intervention Type DRUG

Peginterferon beta-1a

Administered as specified in the treatment arm.

Intervention Type BIOLOGICAL

Ponesimod

Administered as specified in the treatment arm.

Intervention Type DRUG

Siponimod

Administered as specified in the treatment arm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

VUMERITY BIIB098 Tysabri BG00002

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Last menstrual period (LMP) between 29 October 2019 and 31 July 2030.
* Continuous medical and pharmacy coverage for a minimum of 6 months prior to and including the estimated LMP.
* Presence of MS.

Exclusion Criteria

\- Pregnancies will be excluded from this study if they are exposed to any known teratogens from the beginning of baseline through the end of the relevant exposure window.

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No